X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (47023) 47023
Book Review (4383) 4383
Newsletter (3026) 3026
Newspaper Article (2482) 2482
Publication (2212) 2212
Magazine Article (187) 187
Transcript (172) 172
Conference Proceeding (100) 100
Book / eBook (99) 99
Web Resource (80) 80
Book Chapter (78) 78
Trade Publication Article (51) 51
Dissertation (24) 24
Reference (4) 4
Journal / eJournal (3) 3
Government Document (2) 2
Data Set (1) 1
Paper (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (40462) 40462
humans (26757) 26757
male (21892) 21892
animals (19206) 19206
female (16102) 16102
stomach cancer (13667) 13667
cancer (10611) 10611
rats (10239) 10239
middle aged (10156) 10156
oncology (9191) 9191
stomach (8542) 8542
adult (8371) 8371
aged (8181) 8181
stomach neoplasms - pathology (7805) 7805
stomach neoplasms - drug therapy (6915) 6915
gastric cancer (6751) 6751
research (6434) 6434
gastroenterology & hepatology (5660) 5660
stomach - drug effects (5639) 5639
pharmacology & pharmacy (4992) 4992
mice (4912) 4912
chemotherapy (4844) 4844
care and treatment (4424) 4424
abridged index medicus (4365) 4365
gastric mucosa - drug effects (4153) 4153
apoptosis (4152) 4152
cell line, tumor (3775) 3775
health aspects (3581) 3581
analysis (3555) 3555
stomach ulcer - chemically induced (3523) 3523
metastasis (3492) 3492
expression (3395) 3395
surgery (3366) 3366
dose-response relationship, drug (3196) 3196
stomach neoplasms - metabolism (3184) 3184
stomach ulcer - drug therapy (3006) 3006
stomach neoplasms - genetics (2921) 2921
time factors (2774) 2774
treatment outcome (2750) 2750
proteins (2729) 2729
tumors (2726) 2726
helicobacter pylori (2678) 2678
oncology, experimental (2677) 2677
prognosis (2644) 2644
medicine & public health (2613) 2613
gene expression (2557) 2557
cancer therapies (2551) 2551
antineoplastic combined chemotherapy protocols - therapeutic use (2529) 2529
gastric mucosa - pathology (2478) 2478
studies (2405) 2405
rats, wistar (2379) 2379
stomach neoplasms - surgery (2335) 2335
carcinoma (2331) 2331
stomach - metabolism (2308) 2308
genetic aspects (2293) 2293
aged, 80 and over (2273) 2273
risk factors (2238) 2238
stomach - physiology (2215) 2215
rats, sprague-dawley (2144) 2144
drug therapy (2035) 2035
stomach ulcer - prevention & control (1969) 1969
gastroenterology (1967) 1967
dogs (1956) 1956
development and progression (1952) 1952
physiology (1936) 1936
gastric mucosa - metabolism (1892) 1892
in vitro techniques (1839) 1839
medical prognosis (1828) 1828
medicine (1812) 1812
apoptosis - drug effects (1801) 1801
biochemistry & molecular biology (1799) 1799
stomach neoplasms - mortality (1758) 1758
drugs (1676) 1676
patients (1662) 1662
research article (1652) 1652
stomach ulcer - pathology (1649) 1649
immunohistochemistry (1636) 1636
adenocarcinoma - drug therapy (1621) 1621
medical research (1609) 1609
cells (1607) 1607
therapy (1594) 1594
stomach - pathology (1589) 1589
adenocarcinoma (1588) 1588
kinases (1575) 1575
rats, inbred strains (1574) 1574
anti-ulcer agents - therapeutic use (1540) 1540
ulcers (1534) 1534
hydrogen-ion concentration (1493) 1493
medicine, research & experimental (1487) 1487
administration, oral (1484) 1484
cell biology (1474) 1474
disease models, animal (1461) 1461
inhibition (1450) 1450
physiological aspects (1450) 1450
neoplasm staging (1449) 1449
cell proliferation - drug effects (1425) 1425
cell growth (1418) 1418
adenocarcinoma - pathology (1414) 1414
cisplatin (1412) 1412
fluorouracil - administration & dosage (1402) 1402
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (84) 84
Online Resources - Online (3) 3
Collection Dvlpm't (Acquisitions) - Closed Orders (2) 2
Collection Dvlpm't (Acquisitions) - Vendor file (2) 2
UofT at Mississauga - Stacks (2) 2
Credit Valley Hospital - Reference (1) 1
Dentistry (Harry R Abbott) - Stacks (1) 1
Gerstein Science - Reference (1) 1
Lakeridge Health Sciences - Oshawa (1) 1
Markham Stouffville Hospital - Stacks (1) 1
Providence Healthcare - Reference (1) 1
Scarborough Hospital - General (1) 1
St. Michael's Hospital - Stacks (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
Thomas Fisher Rare Book - Rare Book (1) 1
UTL at Downsview - May be requested (1) 1
UofT at Mississauga - Oversize (1) 1
UofT at Mississauga - Reference (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (47989) 47989
Japanese (1642) 1642
Russian (1018) 1018
Chinese (771) 771
German (596) 596
French (356) 356
Italian (216) 216
Spanish (167) 167
Polish (94) 94
Ukrainian (52) 52
Danish (34) 34
Czech (32) 32
Norwegian (26) 26
Swedish (26) 26
Hungarian (24) 24
Romanian (24) 24
Bulgarian (21) 21
Dutch (21) 21
Korean (19) 19
Portuguese (19) 19
Slovak (13) 13
Croatian (6) 6
Turkish (6) 6
Serbian (4) 4
Hebrew (3) 3
Persian (3) 3
Lithuanian (2) 2
Arabic (1) 1
Finnish (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical and Experimental Dermatology, ISSN 0307-6938, 04/2016, Volume 41, Issue 3, pp. 283 - 284
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 2010, Volume 5, Issue 3, pp. e9836 - e9836
Antibiotic administration is the standard treatment for the bacterium Helicobacter pylori, the main causative agent of peptic ulcer disease and gastric cancer.... 
CLARITHROMYCIN | RESISTANCE GENES | INTESTINAL MICROFLORA | HELICOBACTER-PYLORI INFECTION | FLORA | PERSISTENCE | BIOLOGY | POPULATIONS | MACROLIDE RESISTANCE | GRADIENT GEL-ELECTROPHORESIS | 16S RIBOSOMAL-RNA | Oligonucleotides - genetics | Dyspepsia - drug therapy | Humans | Metronidazole - administration & dosage | Omeprazole - administration & dosage | Gastrointestinal Tract - microbiology | Gastrointestinal Tract - drug effects | Drug Resistance, Microbial - genetics | Phylogeny | Case-Control Studies | Anti-Bacterial Agents - therapeutic use | Polymorphism, Restriction Fragment Length | Time Factors | Clarithromycin - administration & dosage | RNA, Ribosomal, 16S - genetics | Feces | Pharynx - drug effects | Pharynx - microbiology | Drug resistance in microorganisms | Care and treatment | Antibiotics | Microbiota (Symbiotic organisms) | RNA | Analysis | Peptic ulcer | Stomach cancer | Antiulcer drugs | Short term | Microbial activity | Clarithromycin | rRNA 16S | Microbiology | Genes | Colorectal cancer | Biology | Drug resistance | Gene polymorphism | Data bases | Microorganisms | Helicobacter pylori | Intestine | Antibiotic resistance | Phylogenetics | Bacteria | Gastric cancer | Deoxyribonucleic acid--DNA | Pharynx | Disease control | Bacteriology | Polymerase chain reaction | Infectious diseases | Restriction fragment length polymorphism | Metronidazole | Cancer | Long-term effects | Polymorphism | Index Medicus | ULCERS | ANTIBIOTICS | DISEASES | THERAPY | NEOPLASMS | GENES | FECES | COMMUNITIES | METRONIDAZOLE | Microbial/genetics | Ribosomal | Pharynx/drug effects/microbiology | Restriction Fragment Length | Gastrointestinal Tract/drug effects/microbiology | Clarithromycin/administration & dosage | Omeprazole/administration & dosage | Metronidazole/administration & dosage | Oligonucleotides/genetics | Naturvetenskap | Natural Sciences | Dyspepsia/drug therapy | 16S/genetics | Anti-Bacterial Agents/therapeutic use | Drug Resistance | Deoxyribonucleic acid | DNA
Journal Article
EMBO Molecular Medicine, ISSN 1757-4676, 10/2014, Volume 6, Issue 10, pp. 1279 - 1293
Epithelial‐mesenchymal transition ( EMT ) is a reversible and dynamic process hypothesized to be co‐opted by carcinoma during invasion and metastasis. Yet,... 
drug response | microarray | gene expression signature | epithelial‐mesenchymal transition | prognosis | Drug response | Epithelial-mesenchymal transition | Prognosis | Microarray | Gene expression signature | MOLECULAR SUBTYPES | MEDICINE, RESEARCH & EXPERIMENTAL | GENE-EXPRESSION SIGNATURE | STEM-CELLS | GENOMIC ANALYSES | OVARIAN-CANCER | NEGATIVE BREAST-CANCER | CLINICAL-RELEVANCE | MICRORNA CONTROL | CLAUDIN-LOW | epithelial-mesenchymal transition | SIGNATURE PREDICTS RESISTANCE | Lung Neoplasms - drug therapy | Oligonucleotide Array Sequence Analysis | Colorectal Neoplasms - genetics | Humans | Epithelial-Mesenchymal Transition - drug effects | Antineoplastic Agents - therapeutic use | Epithelial-Mesenchymal Transition - genetics | Ovarian Neoplasms - genetics | Urinary Bladder Neoplasms - genetics | Neoplasms - genetics | Colorectal Neoplasms - drug therapy | Female | Gene Expression Regulation, Neoplastic - drug effects | Ovarian Neoplasms - drug therapy | Lung Neoplasms - genetics | Stomach Neoplasms - genetics | Treatment Outcome | Transcriptome - drug effects | Transcriptome - genetics | Stomach Neoplasms - drug therapy | Urinary Bladder Neoplasms - drug therapy | Breast Neoplasms - drug therapy | Neoplasms - drug therapy | Disease-Free Survival | Breast Neoplasms - genetics | Cell Line, Tumor | Cancer patients | Chemotherapy | Patient outcomes | Stem cells | Development and progression | Drug therapy | Gene expression | Ovarian cancer | Cancer | Medical research | Breast cancer | Tumors | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2016, Volume 34, Issue 13, pp. 1448 - 1454
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 9, pp. 1007 - 1018
Summary Background Dysregulation of the hepatocyte growth factor (HGF)/MET pathway promotes tumour growth and metastasis. Rilotumumab is a fully human,... 
Hematology, Oncology and Palliative Medicine | ADVANCED SOLID TUMORS | CANCER-PATIENTS | AMPLIFICATION | ONCOLOGY | HEPATOCYTE GROWTH-FACTOR | C-MET | MONOCLONAL-ANTIBODY | CIRCULATING LEVEL | AMG 102 | CARCINOMA | FACTOR/SCATTER FACTOR | Confidence Intervals | Adenocarcinoma - pathology | Esophagogastric Junction - drug effects | Prognosis | Capecitabine | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Stomach Neoplasms - pathology | Dose-Response Relationship, Drug | Fluorouracil - therapeutic use | Deoxycytidine - therapeutic use | Fluorouracil - adverse effects | Neoplasm Invasiveness - pathology | Adult | Deoxycytidine - adverse effects | Female | Double-Blind Method | Drug Administration Schedule | Fluorouracil - analogs & derivatives | Proportional Hazards Models | Esophagogastric Junction - pathology | Survival Rate | Treatment Outcome | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Disease-Free Survival | Maximum Tolerated Dose | Cisplatin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cisplatin - adverse effects | Epirubicin - therapeutic use | Aged | Neoplasm Staging | Stomach Neoplasms - mortality | Deoxycytidine - analogs & derivatives | Adenocarcinoma - mortality | Epirubicin - adverse effects | Monoclonal antibodies | Anthracyclines | Index Medicus
Journal Article
Cancer Letters, ISSN 0304-3835, 2014, Volume 356, Issue 2, pp. 704 - 712
Highlights • We now submit our study entitled “Proton pump inhibitor pantoprazole abrogates adriamycin-resistant gastric cancer cell invasiveness via... 
Hematology, Oncology and Palliative Medicine | Epithelial to mesenchymal transition | Pantoprazole | Drug resistance | Invasiveness | ACQUISITION | PHENOTYPE | DRUG-RESISTANCE | E-CADHERIN | BETA-CATENIN | ADENOCARCINOMA SGC7901 CELLS | ONCOLOGY | COLORECTAL-CANCER | PROSTATE-CANCER | MULTIDRUG-RESISTANCE | EXPRESSION | Proton Pump Inhibitors - pharmacology | Antibiotics, Antineoplastic - pharmacology | Apoptosis - drug effects | Humans | Stomach Neoplasms - metabolism | Epithelial-Mesenchymal Transition - drug effects | Glycogen Synthase Kinase 3 beta | Stomach Neoplasms - pathology | 2-Pyridinylmethylsulfinylbenzimidazoles - pharmacology | Proto-Oncogene Proteins c-akt - genetics | Phosphorylation - drug effects | Tumor Cells, Cultured | Proto-Oncogene Proteins c-akt - metabolism | Real-Time Polymerase Chain Reaction | Wound Healing - drug effects | Tumor Stem Cell Assay | Neoplasm Invasiveness | RNA, Messenger - genetics | Stomach Neoplasms - drug therapy | Glycogen Synthase Kinase 3 - metabolism | Reverse Transcriptase Polymerase Chain Reaction | Blotting, Western | Cell Movement - drug effects | Wnt Signaling Pathway - drug effects | Glycogen Synthase Kinase 3 - genetics | Fluorescent Antibody Technique | Cell Proliferation - drug effects | Doxorubicin - pharmacology | Drug Resistance, Neoplasm - drug effects | Index Medicus
Journal Article
CANCERS, ISSN 2072-6694, 04/2019, Volume 11, Issue 4, p. 560
Gastric cancer is the third leading cause of cancer mortality worldwide. Cancer stem cells (CSC) are at the origin of tumor initiation, chemoresistance, and... 
GENERATES CELLS | PI3K INHIBITOR BKM120 | tumorsphere | STOMACH-CANCER | BKM120 | EPITHELIAL-MESENCHYMAL TRANSITION | metastases | DOSE-ESCALATION | CSC | PI3K | ONCOLOGY | PHASE-I TRIAL | PATHWAY | dissemination | PDOX | DOUBLE-BLIND | BUPARLISIB | gastric carcinoma | CARCINOMA | CD44
Journal Article
Endoscopy, ISSN 0013-726X, 03/2008, Volume 26, Issue 4, pp. 338 - 341
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 08/2014, Volume 20, Issue 15, pp. 3974 - 3988
Purpose: Gastric cancers may harbor a subset of cells with cancer stem cell (CSC) properties, including chemotherapy resistance, and CD44 is a gastric CSC... 
CAPECITABINE | MAINTENANCE | STEM-CELLS | ONCOLOGY | PATHWAY | GROWTH | ADVANCED ESOPHAGOGASTRIC CANCER | SELF-RENEWAL | OXALIPLATIN | LABEL PHASE-3 TRIAL | TUMORIGENICITY | Leucovorin - administration & dosage | RNA, Small Interfering - genetics | Adenocarcinoma - pathology | Prognosis | Receptors, G-Protein-Coupled - metabolism | Apoptosis - drug effects | Neoplastic Stem Cells - drug effects | Humans | Hedgehog Proteins - metabolism | Stomach Neoplasms - metabolism | Drug Resistance, Neoplasm | Stomach Neoplasms - pathology | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Cisplatin - administration & dosage | Adenocarcinoma - metabolism | Flow Cytometry | Fluorouracil - administration & dosage | Smoothened Receptor | Hyaluronan Receptors - metabolism | Neoplastic Stem Cells - pathology | Female | Spheroids, Cellular - drug effects | Tumor Cells, Cultured | Pyridines - administration & dosage | Survival Rate | Hedgehog Proteins - antagonists & inhibitors | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Blotting, Western | Xenograft Model Antitumor Assays | Cell Movement - drug effects | Animals | Anilides - administration & dosage | Signal Transduction - drug effects | Mice, Nude | Fluorescent Antibody Technique | Receptors, G-Protein-Coupled - antagonists & inhibitors | Cell Proliferation - drug effects | Mice | Mice, Inbred BALB C | Receptors, G-Protein-Coupled - genetics | Stomach Neoplasms - mortality | Adenocarcinoma - mortality | Index Medicus
Journal Article
EFFECTS OF DRUGS AND IONIC VARIATIONS ON CONTRACTIONS OF RAT SMOOTH MUSCLES, 12/1999
Chemical agents, Acetylcholine, Ach (5.0 x 10-9 - 4.0 x 10-8 Noradrenaline, NA (6.6 x 10-5 - 5.2 x 10-4M) and Potassium, K+ (25mM, 50mM) which stimulate... 
Smooth muscle, Ileum, Stomach strip, Vas deferens, Contractions, Rat
Journal